[Mezlocillin: tissue concentration and efficacy (author's transl)].
Studies on serum and tissue (cutis, muscle and liver) concentrations were carried out with mezlocillin (Baypen), a semi-synthetic new acyl ureidopenicillin, in 51 patients. Serum half life was 59 minutes. The highest concentrations were measured in the cutis, the lowest in the muscles. Concentrations in the liver were found to be relatively constant and persistent.--The efficacy and tolerance of mezlocillin were examined in 48 patients affected by 56 mostly severe infections, which were treated with a dose of 5 g twice or three times daily. The indications for antibiotic treatment were bronchopulmonary infections, peritonitis, soft tissue infections, biliary and urinary tract infections and postoperative febrile conditions of unknown origin. Clinical cure was achieved in 78.5% and an improvement of symptoms in 5.4% of infections. 76% of the causative microorganisms were eliminated. Mezlocillin was locally and systemically well tolerated.
D004341:Drug Evaluation; D004361:Drug Tolerance; D005335:Fever of Unknown Origin / Q000188:drug therapy; D006207:Half-Life; D006801:Humans; D008099:Liver / Q000032:analysis; D009132:Muscles / Q000032:analysis; D010406:Penicillins / Q000378:metabolism; D012141:Respiratory Tract Infections / Q000188:drug therapy; D012867:Skin / Q000032:analysis; D014552:Urinary Tract Infections / Q000188:drug therapy
D010406:Penicillins
Mezlocillin: Zur Gewebekonzentration und Wirksamkeit.